Correction - FDA approves Roche's Rozlytrek (entrectinib) for people with ROS1-positive, metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumours

Source :: M2 Presswire. August 16, 2019
Publication Year :: 2019
Abstract: M2 PRESSWIRE-August 16, 2019-: Correction - FDA approves Roche's Rozlytrek (entrectinib) for people with ROS1-positive, metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumours (C)1994-2019 M2 COMMUNICATIONS RDATE:16082019 [...]

Subjects :: United States. Food and Drug Administration
Roche Holding AG
Genes
Biotechnology industries
Small cell lung cancer -- Genetic aspects -- Drug therapy
Drug approval
Non-small cell lung cancer -- Genetic aspects -- Drug therapy
Cancer metastasis -- Genetic aspects -- Drug therapy
Tumors
Business
Business, international

Tools